Cogent Biosciences (COGT) Free Cash Flow (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Free Cash Flow of -$87.3 million for Q1 2026, down 30.23% year-over-year from -$125.2 million in Q1 2025, and down 9.28% quarter-over-quarter from -$79.9 million in Q4 2025.
Powered by 
Analysis
Cogent Biosciences (COGT) Free Cash Flow (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Free Cash Flow for 10 consecutive years, with -$87.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 30.23% year-over-year to -$87.3 million; the TTM figure through Mar 2026 stood at -$286.3 million (down 28.48% YoY), while the FY2025 annual figure was -$266.0 million, down 27.66% from the prior year.
- Free Cash Flow fell to -$87.3 million in Q1 2026 per COGT's latest filing, from -$79.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$27.6 million in Q2 2022 and bottomed at -$87.3 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$49.6 million across 5 years, with a median of -$44.4 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 153.17% — and 2023, when it decreased 0.9%.
- Cogent Biosciences' Free Cash Flow stood at -$31.4 million in 2022, then sank by 41.47% to -$44.4 million in 2023, then tumbled by 36.65% to -$60.7 million in 2024, then slumped by 31.76% to -$79.9 million in 2025, then retreated by 9.28% to -$87.3 million in 2026.
- Business Quant data shows COGT's Free Cash Flow at -$87.3 million in Q1 2026, -$79.9 million in Q4 2025, and -$64.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Cogent Biosciences | 5.94 Bn | 5.94 Bn | - | -77.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -77.64 Mn |
| Mar 31, 2026 | -87.33 Mn |
| Dec 31, 2025 | -79.92 Mn |
| Sep 30, 2025 | -64.35 Mn |
| Jun 30, 2025 | -54.67 Mn |
| Mar 31, 2025 | -67.06 Mn |
| Dec 31, 2024 | -60.65 Mn |
| Sep 30, 2024 | -52.26 Mn |
| Jun 30, 2024 | -42.85 Mn |
| Mar 31, 2024 | -52.60 Mn |
| Dec 31, 2023 | -44.39 Mn |
| Sep 30, 2023 | -38.09 Mn |
| Jun 30, 2023 | -33.32 Mn |
| Mar 31, 2023 | -40.62 Mn |
| Dec 31, 2022 | -31.38 Mn |
| Sep 30, 2022 | -37.75 Mn |
| Jun 30, 2022 | -27.60 Mn |
| Mar 31, 2022 | -28.78 Mn |
| Dec 31, 2021 | -21.21 Mn |
| Sep 30, 2021 | -15.27 Mn |